{"id":33032,"date":"2014-10-07T10:39:21","date_gmt":"2014-10-07T14:39:21","guid":{"rendered":"https:\/\/cablemanpro.com\/wallstreetpr\/?p=33032"},"modified":"2014-10-07T10:39:21","modified_gmt":"2014-10-07T14:39:21","slug":"vivus-inc-nasdaqvvus-claims-qsymia-is-effective-in-weight-loss-in-type-2-diabetes-patients","status":"publish","type":"post","link":"https:\/\/cablemanpro.com\/wallstreetpr\/vivus-inc-nasdaqvvus-claims-qsymia-is-effective-in-weight-loss-in-type-2-diabetes-patients-33032","title":{"rendered":"VIVUS, Inc. (NASDAQ:VVUS) Claims Qsymia Is Effective In Weight Loss In Type 2 Diabetes Patients"},"content":{"rendered":"<p style=\"text-align: justify;\">Boston, MA 10\/07\/2014 (wallstreetpr) \u2013\u00a0<strong>VIVUS, Inc. (NASDAQ:VVUS)<\/strong> is claiming that its Qsymia has the potential to treat obese or overweight patients with type 2 diabetes. The company made the disclosure through its paper that was published online in the Diabetes Care journal.<\/p>\n<p style=\"text-align: justify;\"><strong>Studies Undertaken<\/strong><\/p>\n<p style=\"text-align: justify;\">The paper elaborated the clinical results in which, Qsymia was found out to be a helpful in weight management. The therapy, when combined with a reduced calorie diet and increased physical activity helped subjects within the initial body mass index (BMI) range of 30 kg\/m2 to 27\/kg m2 and higher. These subjects necessarily had one weight related medical condition present; that is high blood pressure, high cholesterol or type 2 diabetes.<\/p>\n<p style=\"text-align: justify;\">The author of the paper based their views on results of two randomized placebo-controlled clinical studies spread across 56 weeks. The studies were divided into phase 2 study and phase 3 study. Under these studies, both overweight and obese patients having type 2 diabetes were treated through PHEN\/TPM ER and lifestyle modification. Further, under phase 3, patients were treated with either metformin or diet alone during the entry into the study. While patients under phase 2 had to be dealt with more intensive therapy due to the long duration of diabetes in them.<\/p>\n<p style=\"text-align: justify;\"><strong>Results<\/strong><\/p>\n<p style=\"text-align: justify;\">At the end of 56 weeks, the results of the studies showed that the weight loss in subjects under PHEN\/TPM\/ER was significant by -9.4% then -2.7% attained under placebo. Moreover, the treated patients found less need to follow diabetes medications than those in the placebo group. However, some of the common associated adverse events in the therapy were constipation, paraesthesia and insomnia. Thus, the data is a full proof to establish the fact that weight loss is possible in type 2 diabetes patients when combined with medical therapy. Moreover, the treatment also has a significant impact on cardiometabolic leading to lowering of HbA1c levels.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Boston, MA 10\/07\/2014 (wallstreetpr) \u2013\u00a0VIVUS, Inc. (NASDAQ:VVUS) is claiming that its Qsymia has the potential to treat obese or overweight patients with type 2 diabetes. [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":33033,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":{"twitter_2902945987_2902945987":""},"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[2236],"tags":[2091,10294,2090],"stock_ticker":[],"class_list":["post-33032","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-business","tag-nasdaqvvus","tag-the-diabetes-care-journal","tag-vivus-inc-nasdaqvvus","entry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>VIVUS, Inc. (NASDAQ:VVUS) Claims Qsymia Is Effective In Weight Loss In Type 2 Diabetes Patients - Wall Street PR<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/cablemanpro.com\/wallstreetpr\/vivus-inc-nasdaqvvus-claims-qsymia-is-effective-in-weight-loss-in-type-2-diabetes-patients-33032\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"VIVUS, Inc. (NASDAQ:VVUS) Claims Qsymia Is Effective In Weight Loss In Type 2 Diabetes Patients - Wall Street PR\" \/>\n<meta property=\"og:description\" content=\"Boston, MA 10\/07\/2014 (wallstreetpr) \u2013\u00a0VIVUS, Inc. (NASDAQ:VVUS) is claiming that its Qsymia has the potential to treat obese or overweight patients with type 2 diabetes. [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/vivus-inc-nasdaqvvus-claims-qsymia-is-effective-in-weight-loss-in-type-2-diabetes-patients-33032\" \/>\n<meta property=\"og:site_name\" content=\"Wall Street PR\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/WallStreetPR\/\" \/>\n<meta property=\"article:published_time\" content=\"2014-10-07T14:39:21+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/10\/Achillion-Pharmaceuticals-Inc..jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"259\" \/>\n\t<meta property=\"og:image:height\" content=\"194\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Donna Fago\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Donna Fago\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/vivus-inc-nasdaqvvus-claims-qsymia-is-effective-in-weight-loss-in-type-2-diabetes-patients-33032#article\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/vivus-inc-nasdaqvvus-claims-qsymia-is-effective-in-weight-loss-in-type-2-diabetes-patients-33032\"},\"author\":{\"name\":\"Donna Fago\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/60ece280249b1fa366ae54f87bb8ae84\"},\"headline\":\"VIVUS, Inc. (NASDAQ:VVUS) Claims Qsymia Is Effective In Weight Loss In Type 2 Diabetes Patients\",\"datePublished\":\"2014-10-07T14:39:21+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/vivus-inc-nasdaqvvus-claims-qsymia-is-effective-in-weight-loss-in-type-2-diabetes-patients-33032\"},\"wordCount\":322,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/vivus-inc-nasdaqvvus-claims-qsymia-is-effective-in-weight-loss-in-type-2-diabetes-patients-33032#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/10\/Achillion-Pharmaceuticals-Inc..jpg\",\"keywords\":[\"NASDAQ:VVUS\",\"the Diabetes Care journal\",\"Vivus Inc. (NASDAQ:VVUS)\"],\"articleSection\":[\"Business\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/vivus-inc-nasdaqvvus-claims-qsymia-is-effective-in-weight-loss-in-type-2-diabetes-patients-33032#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/vivus-inc-nasdaqvvus-claims-qsymia-is-effective-in-weight-loss-in-type-2-diabetes-patients-33032\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/vivus-inc-nasdaqvvus-claims-qsymia-is-effective-in-weight-loss-in-type-2-diabetes-patients-33032\",\"name\":\"VIVUS, Inc. (NASDAQ:VVUS) Claims Qsymia Is Effective In Weight Loss In Type 2 Diabetes Patients - Wall Street PR\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/vivus-inc-nasdaqvvus-claims-qsymia-is-effective-in-weight-loss-in-type-2-diabetes-patients-33032#primaryimage\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/vivus-inc-nasdaqvvus-claims-qsymia-is-effective-in-weight-loss-in-type-2-diabetes-patients-33032#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/10\/Achillion-Pharmaceuticals-Inc..jpg\",\"datePublished\":\"2014-10-07T14:39:21+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/vivus-inc-nasdaqvvus-claims-qsymia-is-effective-in-weight-loss-in-type-2-diabetes-patients-33032#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/vivus-inc-nasdaqvvus-claims-qsymia-is-effective-in-weight-loss-in-type-2-diabetes-patients-33032\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/vivus-inc-nasdaqvvus-claims-qsymia-is-effective-in-weight-loss-in-type-2-diabetes-patients-33032#primaryimage\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/10\/Achillion-Pharmaceuticals-Inc..jpg\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/10\/Achillion-Pharmaceuticals-Inc..jpg\",\"width\":259,\"height\":194},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/vivus-inc-nasdaqvvus-claims-qsymia-is-effective-in-weight-loss-in-type-2-diabetes-patients-33032#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"VIVUS, Inc. (NASDAQ:VVUS) Claims Qsymia Is Effective In Weight Loss In Type 2 Diabetes Patients\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"name\":\"Wall Street PR\",\"description\":\"Latest News From WallStreet\",\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\",\"name\":\"Wall Street PR\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"width\":537,\"height\":70,\"caption\":\"Wall Street PR\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/WallStreetPR\/\",\"https:\/\/x.com\/WallstreetPRs\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/60ece280249b1fa366ae54f87bb8ae84\",\"name\":\"Donna Fago\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/06\/f15db860f556e28a86f628554c98485b.jpeg\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/06\/f15db860f556e28a86f628554c98485b.jpeg\",\"caption\":\"Donna Fago\"},\"description\":\"I believe in writing content Informing investors with the knowledge they need to invest better today- I have been following the markets for many years and was asked to join the team at WallStreetPR.com recently due to my passion for the markets.\",\"sameAs\":[\"http:\/\/www.WallStreetPR.com\"],\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/author\/darcie-fago\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"VIVUS, Inc. (NASDAQ:VVUS) Claims Qsymia Is Effective In Weight Loss In Type 2 Diabetes Patients - Wall Street PR","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/cablemanpro.com\/wallstreetpr\/vivus-inc-nasdaqvvus-claims-qsymia-is-effective-in-weight-loss-in-type-2-diabetes-patients-33032","og_locale":"en_US","og_type":"article","og_title":"VIVUS, Inc. (NASDAQ:VVUS) Claims Qsymia Is Effective In Weight Loss In Type 2 Diabetes Patients - Wall Street PR","og_description":"Boston, MA 10\/07\/2014 (wallstreetpr) \u2013\u00a0VIVUS, Inc. (NASDAQ:VVUS) is claiming that its Qsymia has the potential to treat obese or overweight patients with type 2 diabetes. [&hellip;]","og_url":"https:\/\/cablemanpro.com\/wallstreetpr\/vivus-inc-nasdaqvvus-claims-qsymia-is-effective-in-weight-loss-in-type-2-diabetes-patients-33032","og_site_name":"Wall Street PR","article_publisher":"https:\/\/www.facebook.com\/WallStreetPR\/","article_published_time":"2014-10-07T14:39:21+00:00","og_image":[{"width":259,"height":194,"url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/10\/Achillion-Pharmaceuticals-Inc..jpg","type":"image\/jpeg"}],"author":"Donna Fago","twitter_misc":{"Written by":"Donna Fago","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/vivus-inc-nasdaqvvus-claims-qsymia-is-effective-in-weight-loss-in-type-2-diabetes-patients-33032#article","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/vivus-inc-nasdaqvvus-claims-qsymia-is-effective-in-weight-loss-in-type-2-diabetes-patients-33032"},"author":{"name":"Donna Fago","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/60ece280249b1fa366ae54f87bb8ae84"},"headline":"VIVUS, Inc. (NASDAQ:VVUS) Claims Qsymia Is Effective In Weight Loss In Type 2 Diabetes Patients","datePublished":"2014-10-07T14:39:21+00:00","mainEntityOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/vivus-inc-nasdaqvvus-claims-qsymia-is-effective-in-weight-loss-in-type-2-diabetes-patients-33032"},"wordCount":322,"commentCount":0,"publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/vivus-inc-nasdaqvvus-claims-qsymia-is-effective-in-weight-loss-in-type-2-diabetes-patients-33032#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/10\/Achillion-Pharmaceuticals-Inc..jpg","keywords":["NASDAQ:VVUS","the Diabetes Care journal","Vivus Inc. (NASDAQ:VVUS)"],"articleSection":["Business"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/cablemanpro.com\/wallstreetpr\/vivus-inc-nasdaqvvus-claims-qsymia-is-effective-in-weight-loss-in-type-2-diabetes-patients-33032#respond"]}]},{"@type":"WebPage","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/vivus-inc-nasdaqvvus-claims-qsymia-is-effective-in-weight-loss-in-type-2-diabetes-patients-33032","url":"https:\/\/cablemanpro.com\/wallstreetpr\/vivus-inc-nasdaqvvus-claims-qsymia-is-effective-in-weight-loss-in-type-2-diabetes-patients-33032","name":"VIVUS, Inc. (NASDAQ:VVUS) Claims Qsymia Is Effective In Weight Loss In Type 2 Diabetes Patients - Wall Street PR","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/vivus-inc-nasdaqvvus-claims-qsymia-is-effective-in-weight-loss-in-type-2-diabetes-patients-33032#primaryimage"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/vivus-inc-nasdaqvvus-claims-qsymia-is-effective-in-weight-loss-in-type-2-diabetes-patients-33032#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/10\/Achillion-Pharmaceuticals-Inc..jpg","datePublished":"2014-10-07T14:39:21+00:00","breadcrumb":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/vivus-inc-nasdaqvvus-claims-qsymia-is-effective-in-weight-loss-in-type-2-diabetes-patients-33032#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/cablemanpro.com\/wallstreetpr\/vivus-inc-nasdaqvvus-claims-qsymia-is-effective-in-weight-loss-in-type-2-diabetes-patients-33032"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/vivus-inc-nasdaqvvus-claims-qsymia-is-effective-in-weight-loss-in-type-2-diabetes-patients-33032#primaryimage","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/10\/Achillion-Pharmaceuticals-Inc..jpg","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/10\/Achillion-Pharmaceuticals-Inc..jpg","width":259,"height":194},{"@type":"BreadcrumbList","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/vivus-inc-nasdaqvvus-claims-qsymia-is-effective-in-weight-loss-in-type-2-diabetes-patients-33032#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/cablemanpro.com\/wallstreetpr\/"},{"@type":"ListItem","position":2,"name":"VIVUS, Inc. (NASDAQ:VVUS) Claims Qsymia Is Effective In Weight Loss In Type 2 Diabetes Patients"}]},{"@type":"WebSite","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","name":"Wall Street PR","description":"Latest News From WallStreet","publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization","name":"Wall Street PR","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","width":537,"height":70,"caption":"Wall Street PR"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/WallStreetPR\/","https:\/\/x.com\/WallstreetPRs"]},{"@type":"Person","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/60ece280249b1fa366ae54f87bb8ae84","name":"Donna Fago","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/06\/f15db860f556e28a86f628554c98485b.jpeg","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/06\/f15db860f556e28a86f628554c98485b.jpeg","caption":"Donna Fago"},"description":"I believe in writing content Informing investors with the knowledge they need to invest better today- I have been following the markets for many years and was asked to join the team at WallStreetPR.com recently due to my passion for the markets.","sameAs":["http:\/\/www.WallStreetPR.com"],"url":"https:\/\/cablemanpro.com\/wallstreetpr\/author\/darcie-fago"}]}},"_links":{"self":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/33032","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/comments?post=33032"}],"version-history":[{"count":0,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/33032\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media\/33033"}],"wp:attachment":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media?parent=33032"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/categories?post=33032"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/tags?post=33032"},{"taxonomy":"stock_ticker","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/stock_ticker?post=33032"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}